CAPS1 activators are a group of compounds that enhance the activity of Calcium-dependent activator protein for secretion 1 (CAPS1), which is integral to the process of vesicle trafficking and neurotransmitter release in neuronal cells. CAPS1 is known to facilitate the priming of secretory vesicles, preparing them to release their contents upon calcium ion signaling. The activators of this protein typically function by binding to CAPS1 and stabilizing it in a conformation that promotes its interaction with other proteins and membranes involved in vesicle docking and fusion. By augmenting the function of CAPS1, these activators can potentially increase the efficiency and rate of vesicle priming, leading to enhanced readiness for vesicle release. The molecular interaction between CAPS1 activators and their target can involve a direct binding that promotes the protein's intrinsic activity or allosteric modulation that leads to an increased affinity or interaction between CAPS1 and its substrates or associated regulatory proteins.
The discovery and characterization of CAPS1 activators involve detailed studies on the protein's structure and the molecular dynamics of its action. Techniques such as high-throughput screening may be employed to identify lead compounds that can increase CAPS1 activity from vast chemical libraries. Understanding the precise interaction between CAPS1 and its activators allows for the fine-tuning of these compounds to enhance their specificity and potency. As tools for probing the biological functions of CAPS1, activators are valuable in dissecting the mechanisms by which CAPS1 influences vesicle trafficking and the release of neurotransmitters, providing insights into the fundamental processes that underpin synaptic function and neuronal communication.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
8-Bromo-cGMP | 51116-01-9 | sc-200316 sc-200316A | 10 mg 50 mg | $104.00 $354.00 | 7 | |
8-Br-cGMP, a cGMP analogue, activates Protein Kinase G (PKG). PKG activation can increase the sensitivity of calcium channels, leading to increased calcium influx, activating CAPS1 for vesicle priming. | ||||||
Pregnenolone sulfate sodium salt | 1852-38-6 | sc-301609 | 50 mg | $99.00 | 2 | |
This excitatory neurosteroid can modulate NMDA and AMPA receptors, facilitating greater calcium entry. This elevated intracellular calcium can enhance CAPS1's ability to promote vesicle fusion. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $59.00 $173.00 | 15 | |
By modulating L-type calcium channels, Nifedipine can alter calcium dynamics in the cell. Adjustments in calcium concentrations can have downstream effects on CAPS1 activity. | ||||||
Aniracetam | 72432-10-1 | sc-203514 sc-203514A | 50 mg 250 mg | $115.00 $456.00 | ||
Aniracetam potentiates AMPA receptor responses, which can increase calcium entry. Elevated calcium concentrations can subsequently drive CAPS1's vesicle-priming function. | ||||||
FPL-64176 | 120934-96-5 | sc-201491 | 5 mg | $83.00 | 1 | |
Directly activating L-type calcium channels, FPL 64176 promotes increased calcium concentrations in the neuron. This activates CAPS1, further promoting vesicle fusion. | ||||||
BAPTA, Free Acid | 85233-19-8 | sc-201508 sc-201508A | 100 mg 500 mg | $68.00 $267.00 | 10 | |
BAPTA sequesters intracellular calcium. Modulating calcium levels can cause compensatory mechanisms that might indirectly promote CAPS1 activity by altering cellular calcium dynamics. | ||||||
SK&F 96365 | 130495-35-1 | sc-201475 sc-201475B sc-201475A sc-201475C | 5 mg 10 mg 25 mg 50 mg | $103.00 $158.00 $397.00 $656.00 | 2 | |
By inhibiting store-operated calcium channels, SKF 96365 disrupts calcium homeostasis. This disruption can lead to adjustments in cellular mechanisms that indirectly impact CAPS1 activation. | ||||||
Nitrendipine | 39562-70-4 | sc-201466 sc-201466A sc-201466B | 50 mg 100 mg 500 mg | $109.00 $160.00 $458.00 | 6 | |
Nitrendipine, as a calcium channel blocker, alters calcium dynamics within the neuron. This modulation can influence CAPS1's ability to promote vesicle fusion and neurotransmitter release. | ||||||
Isradipine | 75695-93-1 | sc-201467 sc-201467A | 10 mg 50 mg | $88.00 $324.00 | 1 | |
Isradipine's action on L-type calcium channels alters intracellular calcium concentrations, potentially driving CAPS1 activity in vesicle priming. | ||||||
Arachidonic Acid (20:4, n-6) | 506-32-1 | sc-200770 sc-200770A sc-200770B | 100 mg 1 g 25 g | $92.00 $240.00 $4328.00 | 9 | |
By modulating ion channels and affecting intracellular signaling, arachidonic acid may indirectly promote calcium entry, thus enhancing CAPS1's role in vesicle fusion. | ||||||